DVA · CIK 927066
What DaVita Inc. told the SEC could break it.
DaVita's disclosures revolve around its dependence on government reimbursement for dialysis. Commercial payors are only about 32% of U.S. dialysis patient service revenue, so the bulk of its income comes at lower, government-set Medicare and Medicaid rates — and those rates are determined annually by CMS under the ESRD Prospective Payment System, where it received only a 2.2% average increase for 2026 even as more drug classes are folded into the bundle. That reliance on federal machinery extends to operational risk from HHS and CMS staffing cuts that could delay Medicare enrollment and credentialing, and its 14-country international footprint adds exposure to foreign data-protection regimes like Brazil's LGPD and China's Data Security Law, each carrying multimillion-dollar penalties.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- Medicare ESRD Prospective Payment System rate settingmedium
Annual CMS rate-setting under the Medicare ESRD PPS bundle directly drives DaVita's reimbursement — CMS finalized only a 2.2% average rate increase for CY2026 and is folding drug classes (e.g., phosphate binders) into the bundle via TDAPA.
“In November 2025, the Centers for Medicare & Medicaid Services (CMS) issued a final rule to update the Medicare ESRD Prospective Payment System payment rate and policies for calendar year 2026. CMS has finalized ESRD freestanding facilities' average reimbursement by an increase of 2.2% in 2026.”
SEC filing →As of 2026 - HHS/CMS staffing & immigration policylow
Federal staff-reduction policies at HHS/CMS could delay Medicare enrollment, coverage verification, and credentialing, while immigration policy shifts could tighten DaVita's labor market and treatment volumes.
“staff reduction policies at key agencies such as the Department of Health and Human Services and the Centers for Medicare & Medicaid Services (CMS) that may among other things, result in delays in Medicare enrollment, coverage verification, licensing and credentialing approval and may limit the availability of administrative and legal support that, among other things, delays claims resolution or similar processes;”
Customer concentration
- government payor (Medicare) reimbursement dependencehigh
DaVita's U.S. dialysis revenue is dominated by government payors — commercial payors are only ~32% of patient service revenue, so the bulk depends on lower, government-set Medicare/Medicaid reimbursement.
“Commercial payors (including hospital dialysis services) represent approximately 32% of U.S. dialysis patient service revenues.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch